Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Assets (2022 - 2025)

Oramed Pharmaceuticals' Assets history spans 4 years, with the latest figure at $230.9 million for Q4 2025.

  • For Q4 2025, Assets changed N/A year-over-year to $230.9 million; the TTM value through Dec 2025 reached $230.9 million, changed N/A, while the annual FY2025 figure was $230.9 million, N/A changed from the prior year.
  • Assets reached $230.9 million in Q4 2025 per ORMP's latest filing, up from $220.5 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $230.9 million in Q3 2023 to a low of $147.5 million in Q1 2025.
  • Average Assets over 4 years is $182.8 million, with a median of $165.1 million recorded in 2024.
  • Peak YoY movement for Assets: skyrocketed 40.41% in 2023, then dropped 28.5% in 2024.
  • A 4-year view of Assets shows it stood at $161.6 million in 2022, then surged by 36.44% to $220.6 million in 2023, then dropped by 25.15% to $165.1 million in 2024, then skyrocketed by 39.85% to $230.9 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Assets are $230.9 million (Q4 2025), $220.5 million (Q3 2025), and $161.7 million (Q2 2025).